Ernst Hund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ernst Hund has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Cyrus Khandanpour
Clinic for Hematology and Oncology, University Hospital Schleswig-Holstein Campus, 23562 Lübeck, Germany
2 shared publications - Helena Franziska Pernice
Amyloidosis Center Charité Berlin (ACCB), Charité University Medicine, Berlin, Germany
2 shared publications - Katrin Hahn
Amyloidosis Center Charité Berlin (ACCB), Charité University Medicine, Berlin, Germany
2 shared publications - Maike F. Dohrn
Department of Neurology, Medical Faculty, RWTH Aachen University, Aachen, Germany
2 shared publications - Markus Weiler
Heidelberg University Hospital, and Faculty of Medicine, Heidelberg University, BW, Germany
2 shared publications - Sebastian Spethmann
Amyloidosis Center Charité Berlin (ACCB), Charité University Medicine, Berlin, Germany
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Neurological Research and Practice
- Vol. 8 (1) , 63
Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany – expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN)
Hereditary transthyretin (ATTRv) amyloidosis is a rare, progressive multisystem disease caused by pathogenic variants in the transthyretin ( TTR ) gene. ATTRv-associated Polyneuropathy (ATTRv-PN) manifests in a length-dependent sensorimotor and autonomic pattern, commonly accompanied by cardiomyopathy. In recent years, clinical trials have introduced two classes of disease modifying treatments (DMT), TTR stabilizers and gene silencers. Across populations and outcome parameters, all trials share one result disease progression was significantly slowed and patients’ span and quality of life substantially improved compared to placebo, even though a function once lost would not be retrieved. This expert consensus paper provides recommendations for the treatment of ATTRv-PN in Germany and was jointly developed by experts from the German Society of Amyloid Diseases (DGAK) and the German Neurological Society (DGN). In addition to evidence from pivotal clinical trials, the recommendations incorporate benefit assessments of the German Federal Joint Committee (G-BA). For first-line treatment, the DGAK/DGN recommends one of the two second-generation TTR gene-silencing agents, vutrisiran or eplontersen, for most patients with symptomatic ATTRv-PN. For patients showing even minor signs of disease progression under a TTR stabilizer, the authors recommend immediate switch to a gene silencer. Evidence is limited for or against switching between silencers or combining different agents. Informed patient participation is crucial upon initiation and adaptation of DMT. For central nervous system (CNS) involvement, none of the approved agents sufficiently crosses the blood-brain barrier. Aligned with that, there are no observed or expected CNS side effects of any of the DMTs. In the future, next-generation RNA-interference therapies, gene-editing approaches, and amyloid-depleting antibodies are expected to further expand therapeutic options.
- 11 August 2026
- Published by Springer Nature in Neurological Research and Practice
- Vol. 8 (1) , 63
Open AccessDisease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany – expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN)
Hereditary transthyretin (ATTRv) amyloidosis is a rare, progressive multisystem disease caused by pathogenic variants in the transthyretin ( TTR ) gene. ATTRv-associated Polyneuropathy (ATTRv-PN) manifests in a length-dependent sensorimotor and autonomic pattern, commonly accompanied by cardiomyopathy. In recent years, clinical trials have introduced two classes of disease modifying treatments (DMT), TTR stabilizers and gene silencers. Across populations and outcome parameters, all trials share one result disease progression was significantly slowed and patients’ span and quality of life substantially improved compared to placebo, even though a function once lost would not be retrieved. This expert consensus paper provides recommendations for the treatment of ATTRv-PN in Germany and was jointly developed by experts from the German Society of Amyloid Diseases (DGAK) and the German Neurological Society (DGN). In addition to evidence from pivotal clinical trials, the recommendations incorporate benefit assessments of the German Federal Joint Committee (G-BA). For first-line treatment, the DGAK/DGN recommends one of the two second-generation TTR gene-silencing agents, vutrisiran or eplontersen, for most patients with symptomatic ATTRv-PN. For patients showing even minor signs of disease progression under a TTR stabilizer, the authors recommend immediate switch to a gene silencer. Evidence is limited for or against switching between silencers or combining different agents. Informed patient participation is crucial upon initiation and adaptation of DMT. For central nervous system (CNS) involvement, none of the approved agents sufficiently crosses the blood-brain barrier. Aligned with that, there are no observed or expected CNS side effects of any of the DMTs. In the future, next-generation RNA-interference therapies, gene-editing approaches, and amyloid-depleting antibodies are expected to further expand therapeutic options.
- Open Access
- 15 December 2025
- Published by Springer Nature in DGNeurologie
- Vol. 9 (1) , 28-36
Konsilfrage „Amyloidose“ – und jetzt? Nützliches Hintergrundwissen zur Diagnostik und Therapie in der Neurologie
- 15 December 2025
- Published by Springer Nature in DGNeurologie
- Vol. 9 (1) , 28-36
Open AccessKonsilfrage „Amyloidose“ – und jetzt? Nützliches Hintergrundwissen zur Diagnostik und Therapie in der Neurologie
- Open Access
- 7 December 2020
- Published by Taylor & Francis in Amyloid
- Vol. 28 (2) , 91-99
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience
Hereditary transthyretin amyloidosis is caused by pathogenic variants in the TTR gene and typically manifests, alongside cardiac and other organ dysfunctions, with a rapidly progressive sensorimoto...
- 7 December 2020
- Published by Taylor & Francis in Amyloid
- Vol. 28 (2) , 91-99
Open AccessReal-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience
Hereditary transthyretin amyloidosis is caused by pathogenic variants in the TTR gene and typically manifests, alongside cardiac and other organ dysfunctions, with a rapidly progressive sensorimoto...